Last Update03 Oct 25Fair value Decreased 2.26%
Analysts have slightly lowered their average price target for Option Care Health to $37.90 from $38.78. This change reflects updated expectations for profit margins and revenue growth, while recognizing that the company's steady performance is already accounted for in current valuations.
Analyst Commentary
Recent research coverage of Option Care Health highlights both bullish and bearish perspectives, weighing consistent execution against tempered expectations for near-term share gains.
Bullish Takeaways- Bullish analysts have raised price targets in response to strong quarterly results and continued share gains.
- The company is recognized as a leading provider within the home and alternate site infusion market, which supports the case for ongoing long-term growth.
- Its financial position and balanced approach to capital deployment are seen as strengths, providing flexibility for future opportunities.
- Consistent execution is viewed positively and supports confidence in meeting long-term growth targets.
- Bearish analysts note that the company’s solid performance may already be priced into current valuations and this could limit upside potential.
- There is a lack of near-term catalysts identified that could drive significant share appreciation.
- Growth expectations are largely in line with consensus estimates, which constrains arguments for outperformance.
- Some caution is expressed regarding the potential for rapid acceleration beyond already established growth trajectories.
What's in the News
- Barron's highlights Option Care Health as "undervalued," citing strong demand for at-home medical services and a de-risked therapeutic portfolio. The report notes a potential 37% upside despite recent flat share performance. The company has downplayed recent changes in drug pricing, such as those for Stelara, describing these as opportunities for new investors (Barron's).
- Meenal Sethna has been appointed as Chief Financial Officer, effective October 1, 2025. She will succeed Mike Shapiro, who will transition to a Strategic Advisor role during the handover period.
- A strategic relationship has been formed with Quince Therapeutics to enable broad patient access and streamlined administration of Quince’s lead asset, pending further study results and regulatory approval.
- A $50 million share repurchase was completed from April to June 2025, bringing total buybacks since January 2025 to $150.01 million.
- Full-year 2025 earnings guidance has been issued, with net revenue expected to range between $5.50 billion and $5.65 billion.
Valuation Changes
- Consensus Analyst Price Target has decreased from $38.78 to $37.90, reflecting a modest reduction.
- Discount Rate remains unchanged at 6.78%.
- Revenue Growth expectations have risen slightly, moving from 8.78% to 9.27%.
- Net Profit Margin forecast has edged down from 4.43% to 4.25%.
- Future P/E ratio is relatively stable and has increased marginally from 21.59x to 21.70x.
Key Takeaways
- Expansion in high-growth infusion therapies and payer partnerships is broadening patient reach, supporting sustained revenue growth and enhanced pricing power.
- Investments in technology, clinical efficiency, and strategic capital deployment are driving margin improvements, new revenue streams, and long-term earnings expansion.
- Shifting therapy mix, reimbursement risks, and increasing competition threaten margin stability and future revenue growth despite recent gains from competitor exits.
Catalysts
About Option Care Health- Offers home and alternate site infusion services in the United States.
- Growth in both acute and chronic infusion therapies is outpacing the market, driven by demographic shifts (aging population and higher prevalence of chronic/complex conditions), which is expanding Option Care Health's addressable market and positioning the company for sustained revenue growth.
- Deepening partnerships with national payers and pharmaceutical manufacturers-supported by system-wide shifts to lower-cost, value-based care and payers' focus on medical loss ratios-are enhancing contract wins and broadening patient access, supporting revenue growth and pricing power.
- Continued expansion of the company's national suite footprint and advanced practitioner model is improving nurse productivity and enabling the treatment of higher acuity, complex, and new therapeutic cohorts (including oncology and Alzheimer's), driving both margin improvements and new revenue streams.
- Investments in technology (AI, analytics, digital infrastructure) and clinical resource efficiency projects are supporting increased operating leverage and process automation, which is improving net margins and cash flow generation.
- Strategic capital deployment through share repurchases, targeted M&A, and internal investments positions Option Care Health to further accelerate top-line growth and diversify earnings, driving long-term adjusted EPS and earnings expansion.
Option Care Health Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Option Care Health's revenue will grow by 8.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from 3.9% today to 4.4% in 3 years time.
- Analysts expect earnings to reach $306.2 million (and earnings per share of $1.86) by about September 2028, up from $211.3 million today.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 21.6x on those 2028 earnings, down from 22.5x today. This future PE is greater than the current PE for the US Healthcare industry at 21.0x.
- Analysts expect the number of shares outstanding to decline by 4.63% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.
Option Care Health Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Shifts in therapy mix toward lower-margin limited distribution and rare/orphan drugs, while supportive of gross profit dollars, are compressing gross margin rates and could pressure net margins if the mix continues to trend in this direction.
- Dependency on strong payer and pharma relationships, combined with ongoing payer consolidation and attempts to reduce healthcare costs, creates risk of future contract renegotiations or reimbursement rate squeezes, which would threaten revenue and earnings growth.
- Large-scale competitors exiting the market have driven recent acute segment growth, but as these competitor exits become fully annualized and market share gains plateau, organic growth rates may decelerate, potentially impacting top-line revenue expansion.
- The company faces exposure to reimbursement policy changes (e.g., tariffs, Most Favored Nation pricing, site-of-care initiatives), which, while currently not material for 2025, could unpredictably reduce reimbursement or limit profitability in future years, affecting both revenue and net earnings.
- Growth in biosimilars, DIY therapies, and alternative care models could accelerate commoditization of infusion services and increase competition, thereby reducing pricing power and pressuring both revenues and margins over the long term.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $38.778 for Option Care Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $41.0, and the most bearish reporting a price target of just $34.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $6.9 billion, earnings will come to $306.2 million, and it would be trading on a PE ratio of 21.6x, assuming you use a discount rate of 6.8%.
- Given the current share price of $29.25, the analyst price target of $38.78 is 24.6% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives